Loading stock data…
CRBU
$1.80-0.04 (-1.90%)
Market OpenUpdated 3:07 PM EDT
Caribou Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Caribou Biosciences, Inc. in the Healthcare sector is trading at $1.80. Wall Street consensus targets $12.00 (7 analysts), implying a +564.8% move over the next 12 months. The stock is currently 49% below its 52-week high of $3.54, remaining 7.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +564.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.40M↓ | $3.94M↑ | $2.20M↓ | $2.67M↑ | $2.35M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.28M↑ | -$28.45M↑ | -$29.40M↑ | -$35.43M↑ | -$42.91M |
| Net Income | -$25.09M↑ | -$26.49M↑ | -$27.55M↑ | -$54.10M↓ | -$39.99M |
Peer Comparison
JNJUNHPFE
Fundamentals
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-130.58%
Volume
Today's trading volume
718,175
Recent News
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-cel now “pivotal-ready” and its multiple myeloma program CB-011 continuing in Phase 1 development.
Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows
With a stock price of $2.36, Caribou Biosciences, Inc. (NASDAQ:CRBU) is among the 8 Best Up and Coming Penny Stocks to Buy Now. Caribou Biosciences, Inc. (NASDAQ:CRBU) attracted renewed attention after H.C. Wainwright analyst Robert Burns increased his price target on the stock to $11 from $9 on May 11 while maintaining a Buy rating following the […]
May 2026's Promising Penny Stocks
The market remained flat over the last week but is up 25% over the past year, with earnings forecast to grow by 17% annually. In light of these conditions, identifying stocks with strong financials and clear growth potential becomes crucial for investors seeking value. Although the term "penny stocks" may seem outdated, it still points to smaller or less-established companies that can offer significant opportunities; we've identified three such stocks that stand out for their financial...
Industry Analysts Just Made A Massive Upgrade To Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts
Celebrations may be in order for Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders, with the analysts delivering a...
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +21.81% and -4.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?